Ensuring the right PET scan for the right patient.

Area of Science:

• Oncology
• Nuclear Medicine
• Radiology

Background:

• National Institute for Clinical Excellence (NICE) guidelines recommend FDG-PET for non-small-cell lung cancer (NSCLC).
• PET scanning demonstrates high accuracy, sensitivity, and specificity in disease staging and pre-therapeutic assessment for NSCLC.

Purpose of the Study:

• To review the clinical evidence supporting the use of FDG-PET in NSCLC management.
• To highlight the role of PET in radiotherapy planning and outcome prediction.
• To identify areas for further research in PET applications for lung cancer.

Main Methods:

• Review of existing clinical evidence and guidelines regarding FDG-PET in NSCLC.
• Analysis of PET's utility in staging, treatment planning, and response assessment.
• Consideration of PET's potential in surveillance and identifying treatment non-responders.

Main Results:

• PET scanning is accurate for staging NSCLC and assessing suitability for surgery or radiotherapy.
• PET provides valuable data for radiotherapy planning and correlates with treatment response and outcomes.
• Rapid referral and diagnostic processes are crucial for timely PET implementation.

Conclusions:

• FDG-PET has the potential to significantly improve the diagnosis and management of lung cancer.
• Further research is needed to explore new applications, including surveillance and treatment optimization.
• Refinement of guidelines and procedures will maximize the benefits of PET scanning in lung cancer care.